-- 根据FactSet调查的分析师数据，Agilon Health (AGL) 的平均评级为“持有”，平均目标价为27.14美元。 （报道北美、亚洲和欧洲主要银行及研究机构的股票、商品和经济研究。研究机构可通过以下链接联系我们：https://www..com/contact-us）
Related Articles
Research
Research Alert: Bce Reports Better-than-expected Q1 Results On Ai-powered Businesses
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:BCE reported Q1 2026 revenue growth of 4.0% to $6,168M, supported by the Ziply Fiber acquisition, despite a 56.1% dividend reduction to $0.4375. Adjusted EPS of $0.63 beat the consensus of $0.58 but declined 8.7%, as adjusted EBITDA grew 2.9% to $2,631M with margin compression of 40 bps to 42.7%. The Ziply acquisition contributed $234M in revenue and $102M in EBITDA, demonstrating strategic value for BCE's growth opportunities. Management is targeting $1.5B in cost savings by 2028 with capital reallocation flexibility between Canadian and U.S. operations. Wireless showed improved competitive positioning with 16,947 postpaid net additions versus 9,598 losses in Q1 2025, while broadband performance was strong with 17,782 high-speed Internet net additions compared to 3,744 in the prior year. We will listen for updates on cost transformation, regulatory changes impacting fiber resale mandates, and digital media growth on the call.
$BCE
Research
Research Alert: Stratasys: Q1 Revenue Falls 2.5%, Posts Eps Loss Amid Tariff Pressures
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:SSYS reported Q1 revenue of $133M (-2.5% Y/Y), with a 5% products decline partially offset by 4% services growth, while adjusted EPS of -$0.01 beat consensus by $0.01. Adjusted gross margin compressed 200 bps to 46.3%, reflecting tariff and FX headwinds that management has struggled to offset through pricing or cost management. A notable bright spot was Stratasys Direct's 23% organic growth driven by drone applications, while the strong balance sheet with $237.8M cash and zero debt provides stability. Management maintained 2026 guidance of $565M-$575M revenue and $8M-$12.5M adjusted net income, accounting for ~$17M in FX/tariff impacts. We believe recurring consumables revenue and customer support provide defensive characteristics, while management's optimistic tone on defense sector opportunities could drive future growth. The company's emphasis on high-requirement applications, particularly defense contracts expected in 2026 and beyond, represents a potential catalyst.
$SSYS
Research
Research Alert: Cf: Gross Margins Miss Despite Commodity Price Surge Due To Plant Outage
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CF Industries delivered strong Q1 results with EPS of $3.98 versus $1.85 in the prior year and above the $2.66 consensus, while adjusted EBITDA rose 53% to $983M, beating $774M consensus. Net sales increased 19% to $1.99B, exceeding $1.86B consensus, as robust pricing across all segments offset lower volumes from the Yazoo City outage. Exceptional operational execution with 99% ammonia capacity utilization and strategic positioning in a constrained global nitrogen market support the investment thesis. Management projects full-year 2026 gross ammonia production of ~9.5M tons, with Yazoo City resumption not expected until late Q4 2026. We expect the tight global supply-demand balance to persist given Middle East conflict disruptions affecting 50%-60% of regional capacity and LNG supply constraints impacting import-dependent regions. CF's low-carbon initiatives, including the Blue Point joint venture and Yazoo City CCS project, provide structural advantages for long-term value creation.
$CF